In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs

Psychopharmacology

Volumn 162, Issue 2, 2002, Pages 193-202

  Butterweck, Veronika ^a,b   Nahrstedt, Adolf ^a,b   Evans, Jon ^a,b   Hufeisen, Sandy ^a,b   Rauser, Laura ^a,b   Savage, Jason ^a,b   Popadak, Beth ^a,b   Ernsberger, Paul ^a,b   Roth, Bryan L ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Flavonoids; Hyperforin; Hypericin; Hypericum perforatum; Receptor screening; St. John's wort

Indexed keywords

AMENTOFLAVONE; BENZODIAZEPINE RECEPTOR; BETA ADRENERGIC RECEPTOR; DELTA OPIATE RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; FLAVONOID; G PROTEIN COUPLED RECEPTOR; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PSEUDOHYPERICIN; SEROTONIN 1D RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; ANTIDEPRESSANT AGENT; BIOGENIC AMINE; CARRIER PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PLANT EXTRACT; RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SPECIFICITY; HUMAN; HUMAN TISSUE; HYPERICUM PERFORATUM; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; CHEMISTRY; DRUG EFFECT; HERB DRUG INTERACTION; HYPERICUM; METABOLISM; RADIOASSAY; TRANSPORT AT THE CELLULAR LEVEL;

ANTIDEPRESSIVE AGENTS; BIOGENIC AMINES; BIOLOGICAL TRANSPORT; DRUG EVALUATION, PRECLINICAL; FLAVONES; GTP-BINDING PROTEINS; HUMAN; HYPERICUM; MEMBRANE TRANSPORT PROTEINS; PLANT EXTRACTS; RADIOLIGAND ASSAY; RECEPTORS, BIOGENIC AMINE; SUPPORT, U.S. GOV'T, P.H.S.; FLAVONOIDS; HERB-DRUG INTERACTIONS; HUMANS;

EID: 0036019551     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1073-7     Document Type: Article

References (69)

1. Neurotransmitter transporters: Recent progress
2. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum
3. Independent regulation of beta1 and beta2 adrenoceptors
4. Activity profiles of two hyperforin-containing Hypericum extracts in behavioral models
5. Comparison of an extract ofHypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study
6. Dopamine and depression
7. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity
8. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test
9. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test
10. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment
11. St. John's wort, hypericin, and imipramine: A comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats
12. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat
13. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
14. Hyperforin and Hypericum extract: Interaction with some neurotransmitter systems
15. Hyperforin as a possible antidepressant component of Hypericum extracts
16. In vitro binding and enzyme inhibition by Hypericum perforatum extract
17. Pharmacology of St. John's wort: Botanical and chemical aspects
18. The effect of selective serotonin reuptake inhibitors on the cytochrome P450IID6 activity in human liver microsomes
19. Dopamine receptors: Physiological understanding to therapeutic intervention potential
20. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
21. Effect of the tricyclic antidepressant desipramine on α-adrenergic receptors in cultured rat glioma C6 cells
22. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man
23. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex
24. A/benzodiazepine, Sigma, NPY-Y1/Y2 receptors and dopamine transporters
25. Agonist interactions with beta-adrenergic receptor following chronic administration of desipramine or atypical antidepressants, iprindole and mianserin
26. Clinical investigation of the antidepressant effectiveness of Hypericum
27. Chronic exposure of human cells in culture to the tricyclic antidepressant desipramine reduces the number of beta-adrenoceptors
28. Regulation of beta 1-adrenergic receptor mRNA and ligand binding by antidepressant treatment and norepinephrine depletion in rat frontal cortex
29. Neurotransmitter transporters: Fruitful targets for CNS drug discovery
30. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum)
31. Phenolic compounds from Hypericum perforatum
32. Recent advances in molecular recognition and signal transduction of active peptides: Receptor for opioid peptides
33. The molecular biology of serotonin receptors: Therapeutic implications for the interface of mood and psychosis
34. Molecular characteristics of mammalian dopamine receptors
35. St. John's wort in depression: And overview and meta-analysis of randomised clinical trials
36. Neurotransmitter transporters in the central nervous system
37. Interaction of St. John's wort extract with phenprocoumon
38. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia
39. St. John's wort induces hepatic metabolism through activation of the pregnane X receptor
40. Johanniskraut: In-vitro studie über Hypericum-extrakt (LI 160), hypericin und kämpferol als antidepressiva
41. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity
42. Hyperforin represents the neurotransmitter reuptake inhibiting constituent ofHypericum extract
43. Hyperforin: Antidepressant activity by a novel mechanism of action
44. Antidepressant constituents of Hypericum perforatum
45. Biologically active and other chemical constituents of the herb of Hypericum perforatum L.
46. High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro
47. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression
48. 2C receptor
49. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks
50. Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutic responses
51. St. John's wort: Effect on CYP3A4 activity
52. 1C receptors
53. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
54. 2C): Where structure meets function
55. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors
56. Multiplicity of serotonin receptors: Useless diverse molecules or an embarrassment of riches?
57. 2B receptors in the cardiac valvupathy associated with fenfluramine and other serotonergic medications
58. Equivalence of St John's wort extract (Ze 117) and fluoxetine: A randomized, controlled study in mild-moderate depression
59. Effectiveness of St. John's wort in major depression
60. Selective effects of long-term administration of St. John's wort and isolated compounds on beta-adrenergic binding in rat frontal cortex
61. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system
62. Neurochemical studies with St. John's wort in vitro
63. +
64. Inhibition of MAO and COMT by Hypericum extracts and hypericin
65. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generation system in limbic forebrain
66. Controlled clinical trials of Hypericum extracts in depressed patients: An overview
67. Pharmakologische untersuchungen zur antidepressiven wirkung von Hypericum perforatum L.
68. Comparison of St John's wort and imipramine for treating depression: Randomised controlled trial
69. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort